MRK
$114.18-0.02 (-0.02%)
Merck & Co., Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Ze...
Recent News
Big drugmakers saved at least $5bn on US taxes shifting income overseas
Ten of the biggest US pharmaceutical and biotech companies cut at least $5bn from their federal tax bills last year by booking income in low...
H.C. Wainwright Raises Tempus AI (TEM) Price Target to $95
Tempus AI, Inc. (NASDAQ:TEM) is among the 10 Best New AI Stocks to Buy. On March 9, H.C. Wainwright analyst Yi Chen raised the firm’s price target on Tempus AI, Inc. (NASDAQ:TEM) to $95 from $89 while maintaining a Buy rating. The analyst highlighted the company’s expanding network of strategic partnerships, including collaborations with Merck & Co., […]
'My Dad Lost Everything': Jim Cramer 'Willing To Expose' His Father For Picking The Wrong Stock — And Missing Multimillionaire Opportunity
Jim Cramer has long championed individual stock picking, but he also urges investors to know when to walk away from a losing trade. Speaking on the "Big Technology" podcast with Alex Kantrowitz in December, Cramer said investing in individual stocks isn't easy and requires careful research and attention to major trend shifts. He shared the story of his father, who kept investing in the now-defunct video rental company National Video and ended up losing everything. "My dad lost everything on Nati
iBio Touts Bispecific Antibody Strategy for PH-HFpEF, Eyes Development Candidate in Q3
Executives at iBio (NASDAQ:IBIO) outlined the scientific and strategic rationale for a myostatin/activin A bispecific antibody program that the company believes could become a next-generation therapy for heart failure, with an initial focus on pulmonary hypertension associated with heart failure wit
How The Investment Story For Merck KGaA (XTRA:MRK) Is Quietly Shifting On Cautious Targets
A small reset in fair value to €143.20, together with individual analyst targets moving to €135 from €150 and to €130 from €125, has put fresh focus on how Merck KGaA is being framed right now. These moves line up with a mix of more cautious voices trimming targets and at least one bank still seeing room for upside while adjusting expectations. Read on to see how to interpret these shifts and keep track of the story as it develops. Analyst Price Targets don't always capture the full story...